A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Administration of TEV-48125 (Single Ascending Doses and Single Doses up to 900 mg) in Japanese and Caucasian Healthy Subjects

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Administration of TEV-48125 (Single Ascending Doses and Single Doses up to 900 mg) in Japanese and Caucasian Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Fremanezumab (Primary)
  • Indications Migraine
  • Focus Pharmacokinetics
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 05 Sep 2017 According to a Teva Pharmaceutical media release, data will be presented at at the 18th Congress of the International Headache Society (IHC).
    • 20 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 04 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top